Find us on:

LDNscience® is a public information project of the MedInsight® Research Institute.

MedInsight® Research Institute is a U.S./U.K. based non-profit organization established in 2006, that serves as a platform for researching and indexing available off-label (repurposed) treatments for cancer and chronic diseases. MedInsight employs a graph-oriented database to drive innovation in the field of drug repurposing.

Under the leadership of Moshe Rogosnitzky, a scientist and MedInsight's co-founder, LDNscience brings together research and information on Low Dose Naltrexone (LDN) and its application in the treatment of chronic and serious diseases.

We collaborate with LDN researchers to bring current information about clinical trials and research to patients, the general public and professional community.

Click on Our People to learn more about the people behind the great work at LDNscience.

MedInsight's Other Initiatives

The world’s first academic drug repurposing center at Ariel University, CDR utilizes academic expertise and resources to expedite the development of new cures using existing drugs benefiting patients worldwide.

An online knowledge base that serves precision medicine and drug rediscovery, and a collaborative effort between MedInsight Research Institute and Ariel University’s Center for Drug Repurposing, Cureiosity enables patients to benefit from real-life target-driven drug repurposing opportunities.

A non-profit project of MedInsight Research Institute established in 2015 to freely disseminate information about the new eye-disorder repurposed drug, “dipyridamole”.

A crowd-funding non-profit organization (501(c)(3)) that connects donors with research projects. Its aim is to find new cures using existing drugs.